COVID-19 Vaccine Clinical Trials: A Bird's Eye Perspective.
clinical trials in all phases (i-iv)
covid 19
covid-19 vaccine
covid-2019
infectious and tropical diseases
preventive health
sars-cov-2
severe acute respiratory syndrome coronavirus-2 (sars-cov-2)
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
Aug 2022
Aug 2022
Historique:
accepted:
16
08
2022
entrez:
19
9
2022
pubmed:
20
9
2022
medline:
20
9
2022
Statut:
epublish
Résumé
Several Phase-III clinical studies investigating vaccine safety and effectiveness have been published a year following the first breakout of the COVID-19 pandemic. These vaccine candidates were produced using a variety of vaccination technologies, including mRNA, recombinant protein, adenoviral vector, and inactivated virus-based platforms, by various research organizations and pharmaceutical firms. Despite many successful clinical studies, participants are restricted by trial inclusion and exclusion criteria, geographic location, and the current state of the virus epidemic. Many concerns remain, particularly for specific populations such as the elderly, women who are pregnant or nursing, and teenagers. Vaccine effectiveness against asymptomatic infection and particular viral variations, on the other hand, is still largely unclear. This review will focus on vaccination candidates that have completed Phase-III clinical trials and will examine the scientific evidence that has been gathered so far for these vaccine candidates for various subgroups of individuals and virus variations.
Identifiants
pubmed: 36120231
doi: 10.7759/cureus.28066
pmc: PMC9477158
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
e28066Informations de copyright
Copyright © 2022, Vallivedu Chennakesavulu et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
J Clin Invest. 2021 Mar 1;131(5):
pubmed: 33444286
Lancet. 2021 Jan 9;397(10269):99-111
pubmed: 33306989
Intervirology. 2022;65(2):104-109
pubmed: 34544075
N Engl J Med. 2021 Sep 23;385(13):1172-1183
pubmed: 34192426
MMWR Morb Mortal Wkly Rep. 2021 Aug 13;70(32):1094-1099
pubmed: 34383735
N Engl J Med. 2020 Dec 10;383(24):2320-2332
pubmed: 32877576
Semin Immunopathol. 2020 Oct;42(5):619-634
pubmed: 33159214
BMC Infect Dis. 2022 Mar 20;22(1):270
pubmed: 35307024
Lancet Infect Dis. 2021 Feb;21(2):181-192
pubmed: 33217362
N Engl J Med. 2021 May 20;384(20):1899-1909
pubmed: 33951374
Immunol Lett. 2021 Feb;230:63-64
pubmed: 33400966
Lancet. 2021 Jan 9;397(10269):72-74
pubmed: 33306990
N Engl J Med. 2020 May 21;382(21):1969-1973
pubmed: 32227757
J Drug Deliv Sci Technol. 2022 Aug;74:103553
pubmed: 35783677
Pediatr Res. 2021 Nov;90(5):966-970
pubmed: 33627824
Sci Transl Med. 2020 Nov 4;12(568):
pubmed: 33077678
Nature. 2020 Oct;586(7830):578-582
pubmed: 32731258
N Engl J Med. 2020 Oct 15;383(16):1544-1555
pubmed: 32722908
Science. 2021 Mar 12;371(6534):1152-1153
pubmed: 33514629
Obesity (Silver Spring). 2022 Mar;30(3):606-613
pubmed: 34850576
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
Nature. 2021 Apr;592(7855):616-622
pubmed: 33567448
N Engl J Med. 2021 Dec 16;385(25):2348-2360
pubmed: 34587382
Hum Vaccin Immunother. 2021 Sep 2;17(9):2954-2956
pubmed: 34033732
BMC Public Health. 2021 Jan 9;21(1):104
pubmed: 33422039
Lancet. 2020 Nov 14;396(10262):1595-1606
pubmed: 33065034
N Engl J Med. 2020 Nov 26;383(22):e121
pubmed: 33064382
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
N Engl J Med. 2021 May 13;384(19):1824-1835
pubmed: 33440088
Nat Commun. 2021 Jan 14;12(1):372
pubmed: 33446655
N Engl J Med. 2020 Dec 17;383(25):2439-2450
pubmed: 33053279
N Engl J Med. 2021 Jan 7;384(1):80-82
pubmed: 33270381
BMJ. 2020 May 4;369:m1790
pubmed: 32366511